You are here

  • Home
  • Archive
  • Volume 10, Issue 9
  • Nemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer

Article metrics

Article menu

This article has a correction. Please see:

Clinical/translational cancer immunotherapy
Original research
Nemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer

 

Online download statistics by month:

Online download statistics by month: September 2022 to July 2025

AbstractFullPdf
Sep 2022448450109
Oct 202234934964
Nov 202230030265
Dec 2022453455184
Jan 202328728747
Feb 202328328770
Mar 202325025156
Apr 202319819940
May 202318818946
Jun 202318518630
Jul 202316616735
Aug 202317717838
Sep 202318918940
Oct 202323023156
Nov 202319919952
Dec 202318318350
Jan 202411811966
Feb 2024868635
Mar 202414014168
Apr 202413413550
May 202414014149
Jun 202410610542
Jul 202412612840
Aug 2024969630
Sep 202470701801
Oct 2024777849
Nov 202412212335
Dec 202412612868
Jan 202510910953
Feb 202511411440
Mar 2025848457
Apr 2025858538
May 2025989956
Jun 2025525325
Jul 2025110
Total596959973584